UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1 )*
SHAMAN PHARMACEUTICALS, INC.
(Name of Issuer)
Common Stock, $.001 par value
(Title of Class of Securities)
819319401
(CUSIP Number)
December 31, 1999
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).
</PAGE>
SCHEDULE 13G
CUSIP NO. 819319401 PAGE 2 OF 8 PAGES
- - ------------------------------------------------------------------------- -
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Advantage Fund II Ltd.
- - ------------------------------------------------------------------------- -
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A)[ ]
(B)[ ]
- - ------------------------------------------------------------------------- -
3 SEC USE ONLY
- - ------------------------------------------------------------------------- -
4 CITIZENSHIP OR PLACE OF ORGANIZATION
British Virgin Islands
- - ------------------------------------------------------------------------- -
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY ---------------------------------------------------- -
EACH 6 SHARED VOTING POWER
REPORTING
PERSON 3,563,635
WITH: ---------------------------------------------------- -
7 SOLE DISPOSITIVE POWER
-0-
---------------------------------------------------- -
8 SHARED DISPOSITIVE POWER
3,563,635
- - ------------------------------------------------------------------------- -
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,563,635
- - ------------------------------------------------------------------------- -
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
- - ------------------------------------------------------------------------- -
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.48%
- - ------------------------------------------------------------------------- -
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- - ------------------------------------------------------------------------- -
</PAGE>
SCHEDULE 13G
CUSIP NO. 819319401 PAGE 3 OF 8 PAGES
- - ------------------------------------------------------------------------- -
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Genesee Fund Limited - Portfolio B
- - ------------------------------------------------------------------------- -
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A)[ ]
(B)[ ]
- - ------------------------------------------------------------------------- -
3 SEC USE ONLY
- - ------------------------------------------------------------------------- -
4 CITIZENSHIP OR PLACE OF ORGANIZATION
British Virgin Islands
- - ------------------------------------------------------------------------- -
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY ---------------------------------------------------- -
EACH 6 SHARED VOTING POWER
REPORTING
PERSON 415,050
WITH: ---------------------------------------------------- -
7 SOLE DISPOSITIVE POWER
-0-
---------------------------------------------------- -
8 SHARED DISPOSITIVE POWER
415,050
- - ------------------------------------------------------------------------- -
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
415,050
- - ------------------------------------------------------------------------- -
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
- - ------------------------------------------------------------------------- -
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
0.52%
- - ------------------------------------------------------------------------- -
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- - ------------------------------------------------------------------------- -
</PAGE>
SCHEDULE 13G
CUSIP NO. 819319401 PAGE 4 OF 8 PAGES
- - ------------------------------------------------------------------------- -
1 NAME OF REPORTING PERSON
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Genesee International, Inc.
- - ------------------------------------------------------------------------- -
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A)[ ]
(B)[ ]
- - ------------------------------------------------------------------------- -
3 SEC USE ONLY
- - ------------------------------------------------------------------------- -
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- - ------------------------------------------------------------------------- -
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY ---------------------------------------------------- -
EACH 6 SHARED VOTING POWER
REPORTING
PERSON 3,978,685
WITH: ---------------------------------------------------- -
7 SOLE DISPOSITIVE POWER
-0-
---------------------------------------------------- -
8 SHARED DISPOSITIVE POWER
3,978,685
- - ------------------------------------------------------------------------- -
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,978,685
- - ------------------------------------------------------------------------- -
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
- - ------------------------------------------------------------------------- -
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.98%
- - ------------------------------------------------------------------------- -
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
CO
- - ------------------------------------------------------------------------- -
</PAGE>
SCHEDULE 13G
CUSIP NO. 819319401 PAGE 5 OF 8 PAGES
- - ------------------------------------------------------------------------- -
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
Donald R. Morken
- - ------------------------------------------------------------------------- -
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A)[ ]
(B)[ ]
- - ------------------------------------------------------------------------- -
3 SEC USE ONLY
- - ------------------------------------------------------------------------- -
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- - ------------------------------------------------------------------------- -
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY ---------------------------------------------------- -
EACH 6 SHARED VOTING POWER
REPORTING
PERSON 3,978,685
WITH: ---------------------------------------------------- -
7 SOLE DISPOSITIVE POWER
-0-
---------------------------------------------------- -
8 SHARED DISPOSITIVE POWER
3,978,685
- - ------------------------------------------------------------------------- -
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,978,685
- - ------------------------------------------------------------------------- -
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES (SEE INSTRUCTIONS) [ ]
- - ------------------------------------------------------------------------- -
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
4.98%
- - ------------------------------------------------------------------------- -
12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IN
- - ------------------------------------------------------------------------- -
</PAGE>
SCHEDULE 13G
CUSIP NO. 819319401 PAGE 6 OF 8 PAGES
AMENDMENT NO. 1 TO SCHEDULE 13G
This Amendment No. 1 to the initial statement on Schedule 13G filed
December 10, 1999 (the "Initial Statement") by Advantage Fund II Ltd., a
British Virgin Islands corporation ("Advantage"), Genesee Fund Limited -
Portfolio B, a British Virgin Islands corporation ("Genesee Fund"), Genesee
International, Inc., a Delaware corporation ("Genesee International"), and
Donald R. Morken ("Mr. Morken", and collectively with Advantage, Genesee Fund
and Genesee International, the "Reporting Persons") relates to the Common
Stock, $.001 par value (the "Common Stock"), of Shaman Pharmaceuticals, Inc.,
a Delaware corporation (the "Issuer"). Capitalized terms used herein without
definition shall have the meanings given them in the Initial Statement. This
Amendment No. 1 is being filed by the Reporting Persons to report that each of
the Reporting Persons has ceased to be the beneficial owner of more than five
percent of the Common Stock. This Amendment No. 1 amends the Initial
Statement as follows:
Item 4. Ownership:
(a) Amount Beneficially Owned by Advantage, Genesee Fund,
Genesee International and Mr. Morken:
Advantage: 3,563,635
Genesee Fund: 415,050
Genesee International: 3,978,685
Mr. Morken: 3,978,685
(b) Percent of Class:
Advantage: 4.48%
Genesee Fund: 0.52%
Genesee International: 4.98%
Mr. Morken: 4.98%
The Issuer advised Genesee International that
79,182,372 shares of Common Stock were outstanding
as of December 31, 1999. This amount was used to
determine the percentages of outstanding shares
of Common Stock reported in this statement.
(c) Number of Shares as to which the Person has:
(i) sole power to vote or to direct
the vote
Advantage: -0-
Genesee Fund: -0-
Genesee International: -0-
Mr. Morken: -0-
(ii) shared power to vote or to
direct the vote
Advantage: 3,563,635
Genesee Fund: 415,050
Genesee International: 3,978,685
Mr. Morken: 3,978,685
</PAGE>
SCHEDULE 13G
CUSIP NO. 819319401 PAGE 7 OF 8 PAGES
(iii) sole power to dispose or to
direct the disposition of
Advantage: -0-
Genesee Fund: -0-
Genesee International: -0-
Mr. Morken: -0-
(iv) shared power to dispose or to
direct the disposition of
Advantage: 3,563,635
Genesee Fund: 415,050
Genesee International: 3,978,685
Mr. Morken: 3,978,685
The shares of Common Stock reported above in this Item 4
as beneficially owned by the Reporting Persons are reported
as of the close of business on December 31, 1999 and
consist of (1) shares owned directly by Advantage and
(ii) shares issuable to Advantage and Genesee Fund upon
the exercise of certain warrants of the Issuer (the
"Warrants") to purchase shares of Series R Convertible
Preferred Stock of the Issuer (the "Series R Preferred
Stock"), which shares are in turn convertible into shares
of Common Stock. In accordance with the terms of the Series
R Preferred Stock, if Advantage and Genesee Fund exercise
their Warrants they may be entitled to receive additional
shares of Common Stock when the Series R Preferred Stock
first becomes convertible, and is automatically converted,
into shares of Common Stock on February 1, 2000.
Item 5. Ownership of Five Percent or Less of a Class:
If this statement is being filed to report the fact that
as of the date hereof each of the Reporting Persons ceased
to be the beneficial owner of more than five percent of the
class of securities, check the following [X].
</PAGE>
SCHEDULE 13G
CUSIP NO. 819319401 PAGE 8 OF 8 PAGES
SIGNATURE
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is
true, complete and correct.
ADVANTAGE FUND II LTD.
By: Genesee International, Inc.,
as General Manager
By:
---------------------------
Name: Donald R. Morken
Title: President
Dated: January 12, 2000
GENESEE FUND LIMITED - PORTFOLIO B
By: Genesee International, Inc.,
as General Manager
By:
---------------------------
Name: Donald R. Morken
Title: President
Dated: January 12, 2000
GENESEE INTERNATIONAL, INC.
By:
---------------------------------
Name: Donald R. Morken
Title: President
Dated: January 12, 2000
---------------------------
Donald R. Morken
Dated: January 12, 2000
42.46.04.10
